Inhibitor Therapeutics, Inc. Balance Sheet
INTI|7 years of annual SEC 10-K data (FY2014-FY2021)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 7 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Total Assets
$58,784
FY2021
Cash
$30,626
Cash and equivalents
Total Debt
N/A
FY2021
Shareholder Equity
-$4M
FY2021
Inhibitor Therapeutics, Inc. had $58,784 in total assets with negative shareholders' equity of $4M as of FY2021.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -856.15 (distress zone, below 1.23 threshold)
- Piotroski F-Score: 2/9 criteria passed
- Negative shareholders equity: Liabilities exceed assets
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2021 | FY2020 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $30.6K | $75.1K | $1.1M | $344.1K | $6.9M | $601.4K | $365.2K |
| Current Assets | $58.8K | $107.4K | $1.2M | $655.8K | $7.2M | $635.9K | $463.0K |
| Total Assets | $58.8K | $131.8K | $1.2M | $768.1K | $7.3M | $885.9K | $463.0K |
| Current Liabilities | $679.6K | $425.4K | $700.6K | $601.5K | $308.1K | $461.9K | $400.9K |
| Shareholders' Equity | -$3.6M | -$3.4M | $32.4K | $166.6K | $7.0M | $424.0K | $62.1K |